| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| SPRO | SPRO | Shares | USD | XNGS |
| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| SPRO | SPRO | Shares | USD | XNGS |
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, with a focus on SP001, a third-generation anti-CD40L antibody for IgG4-related disease. The company prioritizes programs that align with compelling biology, patient need, and differentiation from existing treatments. SP001 aims to inhibit a key immune signaling pathway to reduce disease activity while preserving immune cell function. Spero is also evaluating SP001's potential in other immune-mediated conditions.
No recent RNS announcements for SPRO across SPRO.
No recent RNS announcements for SPRO across SPRO.